Neurology
We explore the depths of the brain to develop solutions for neurological conditions that impact millions of people worldwide. This constant driver of innovation enables us to charter new paths to life-transforming treatments.
A Decade of Innovation
Our commitment to neurology and the people living with these disorders has been unwavering. From helping to manage partial-onset (focal) seizures of epilepsy to supporting those living with Parkinson’s disease (PD), our ingenuity and innovative spirit are what helps us develop novel treatments that address the daily challenges people encounter living with serious neurological conditions.
Parkinson’s disease*
10M
100K
Epilepsy*
50M
300K
Our Medicines
KYNMOBI® (apomorphine hydrochloride) is indicated for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease.
For more information, please visit:
www.kynmobi.ca
APTIOM® (eslicarbazepine acetate) is indicated as:
- Monotherapy in the management of partial-onset seizures in adult patients with epilepsy. All patients who participated in the monotherapy trial were newly or recently diagnosed with epilepsy
- Adjunctive therapy in the management of adults, and children above 6 years of age, with partial-onset seizures who are not satisfactorily controlled with conventional therapy.